Termination of Partnerships with Other Companies
First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2026.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2026, 6 years after the typical company in this theme (2020).
The whole theme swung hardest in 2025: 6 of 28 companies on the "Worse" side.
3 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Our group promotes an alliance strategy to make effective use of external resources and has business alliances with pharmaceutical companies and others in Japan and overseas involving in-licensing and out-licensing of technologies, contract sales, contract manufacturing, joint sales and joint research. If these alliances are terminated, or if there is a significant change in an alliance partner’s business strategy or business environment, our group’s results of operations and financial position may be materially affected. In addition, business alliances with biotech ventures have become more common in recent years, and an alliance partner’s financial position may affect the continuation of the business alliance.」
The explanation of the risk of alliance termination was expanded to include changes in alliance partners’ business strategies and environments, as well as the risk that the financial position of biotech ventures may affect the continuation of alliances. - FY2019RestatedAnnual report
「If these partnerships are terminated in the future for any reason, this could affect projected business results and other performance indicators.」
The company continues to disclose the risk that termination of alliances involving contract sales, joint sales and joint research may affect results. - FY2018RestatedAnnual report
「If these partnerships are terminated in the future for any reason, this could affect projected business results and other performance indicators.」
The company continues to disclose the risk that termination of alliances involving contract sales, joint sales and joint research may affect results. - FY2017First statedAnnual report
「If these partnerships are terminated in the future for any reason, this could affect projected business results and other performance indicators.」
The termination of outsourcing, co-selling, co-research and other partnerships is identified as a risk to business results.